Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of polysialylated erythropoietin (ErepoXen) versus Aranespin in pre-dialysis CKD patients for the treatment of anemia

Next Previous
Search
Trial Profile

A phase III trial of polysialylated erythropoietin (ErepoXen) versus Aranespin in pre-dialysis CKD patients for the treatment of anemia

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recombinant erythropoietin (Primary) ; Darbepoetin alfa
  • Indications Anaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 17 Mar 2021 According to a Xenetic Biosciences media release, the company's partner, PJSC Pharmsynthez, announced positive results and filed a registration dossier in Russia to obtain approval of Epolong a polysialylated form of human erythropoietin as a treatment for anemia in patients with chronic kidney disease.
    • 16 Feb 2021 According to a Xenetic Biosciences media release, Pharmsynthez reported in its press release that it expects that the Russian stage of registration activities will be completed in 2021
    • 09 Dec 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top